The new discipline aims to address sustainability gaps in the entire life-cycle of medicines, from drug discovery to end-of-life, and reduce the environmental footprint of pharmaceuticals. The University […]
A study that introduces a new strategy to promote customized, oral health self-care by using an online platform to connect dental professionals and patients will be presented at […]
A recent publication described the holistic approach to drug therapy in a patient with heart failure – an area where treatment has changed considerably over the past 30 […]
The management of heart failure treatment is probably best done by a primary care team and pharmacists can play a major role in prescribing, says Paul Forsyth, Lead […]
The key challenges in heart failure treatment include reaching the target dose, awareness of drug-specific issues that influence effectiveness and tackling adherence problems, according to Paul Forsyth, Lead […]
Current thinking advocates the use of ‘four pillars of heart failure therapy’. Paul Forsyth, Lead Pharmacist, Clinical Cardiology at NHS Greater Glasgow and Clyde, explains how this treatment […]
A recent publication described the holistic approach to drug therapy in a patient with heart failure – an area where treatment has changed considerably over the past 30 […]
During the pandemic, contact tracing apps kept Americans informed of potential exposure risk with the goal of reducing infections. But did apps like this help reduce the spread […]
An investigator with the University of Kansas School of Pharmacy has filed an invention disclosure, part of a provisional patent application with the United States Patent and Trademark […]
The European Medicines Agency (EMA) has approved two new medicines at its May meeting. This brings to 30, the number of products given the green light by the […]
Not only is alcohol one of the world’s most abused drugs, but alcohol-related deaths trail only tobacco, poor diet and physical activity, and illegal drugs as the leading […]
The U.S. government could save taxpayers between $228 million-$2.15 billion a year if insurers who operate its Medicare Part D plans purchased seven generic oncology drugs at the […]
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.
